1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Cancer Market Trends
  5. > Seegene, Inc. (096530) - Product Pipeline Analysis, 2016 Update

Summary

Seegene, Inc. (Seegene) is a biotechnology company that develops new technologies for accurate diagnosis. The company’s products comprise Seeplex, Anyplex, and Magicplex among others. It develops ACP, DPO, READ, MuDT and TOCE technologies that enables to detect multiple pathogens in single reactions using Real-time PCR methods. Seegene’s IVD reagents are used in testing respiratory pathogen, gastrointestinal pathogen, sexually transmitted infections, human papillomavirus, tuberculosis, sepsis and meningitis pathogen. The company caters to commercial laboratories, DNA chip-based companies and molecular diagnostic companies. It has operations in the US, Canada, Germany and others. Seegene is headquartered in Seoul, South Korea.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Seegene, Inc.
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Table Of Contents

Seegene, Inc. (096530) - Product Pipeline Analysis, 2016 Update
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 5
Seegene, Inc. Company Overview 6
Seegene, Inc. Company Snapshot 6
Seegene, Inc. Pipeline Products and Clinical Trials Overview 7
Seegene, Inc. - Pipeline Analysis Overview 10
Key Facts 10
Seegene, Inc. - Major Products and Services 11
Seegene, Inc. Pipeline Products by Development Stage 12
Seegene, Inc. Pipeline Products Overview 14
Allplex 26-target Respiratory Full Panel 14
Allplex 26-target Respiratory Full Panel Product Overview 14
Allplex 27-target Sexually Transmitted Infection Full Panel 15
Allplex 27-target Sexually Transmitted Infection Full Panel Product Overview 15
Allplex Gastrointestinal Full Panel Assay 16
Allplex Gastrointestinal Full Panel Assay Product Overview 16
Anyplex II HPV HR 17
Anyplex II HPV HR Product Overview 17
Anyplex II HSV-1/2 Assay 18
Anyplex II HSV-1/2 Assay Product Overview 18
DPO-Based BD Max Assay 19
DPO-Based BD Max Assay Product Overview 19
MDx - Cholangiocarcinoma 20
MDx - Cholangiocarcinoma Product Overview 20
MDx - Colon Cancer 21
MDx - Colon Cancer Product Overview 21
MDx - Non Small Cell Lung Cancer 22
MDx - Non Small Cell Lung Cancer Product Overview 22
MDx - Pancreatic Cancer 23
MDx - Pancreatic Cancer Product Overview 23
MuDT-Based BD Max Assay 24
MuDT-Based BD Max Assay Product Overview 24
Seeplex Sepsis ID Set 25
Seeplex Sepsis ID Set Product Overview 25
TOCE-Based BD Max Assay 26
TOCE-Based BD Max Assay Product Overview 26
Seegene, Inc. - Key Competitors 27
Seegene, Inc. - Key Employees 28
Seegene, Inc. - Locations And Subsidiaries 29
Head Office 29
Other Locations and Subsidiaries 29
Recent Developments 30
Seegene, Inc., Recent Developments 30
Aug 02, 2016: Seegene to Introduce Automated Development of in silico-based Multiplex Real-time PCR Assays 30
Jun 08, 2016: Seegene to Introduce Novel Real-Time PCR Technology at ASM Microbe 2016 30
Mar 07, 2016: Seegene Technologies to Unleash Customized Multiplex PCR Solutions and Support for U.S. Market 31
Jan 04, 2016: Seegene's HPV DNA assay proves its excellent performance in WHO global HPV LabNet study 32
Jul 08, 2015: QIAGEN Expands QIAsymphony Test Menu in Partnership with Seegene 32
May 26, 2015: Seegene Receives CE Mark for First Comprehensive Real-Time PCR Gastrointestinal Infection Panels 33
Apr 22, 2015: Seegene to Attend ECCMID 2015 Annual Meeting 33
Apr 07, 2015: Seegene Establishes U.S. Subsidiary 33
Mar 02, 2015: Seegene Receives Health Canada Approval for its new Allplex Respiratory Molecular Test 34
Feb 17, 2015: FDA Grants 510(k) Clearance For Seegene's HSV Molecular Test 34
Appendix 36
Methodology 36
About GlobalData 36
Contact Us 36
Disclaimer 36

List of Tables
Seegene, Inc. Pipeline Products and Clinical Trials Overview 7
Seegene, Inc. Pipeline Products by Equipment Type 7
Seegene, Inc. Pipeline Products by Indication 9
Seegene, Inc., Key Facts 10
Seegene, Inc., Major Products and Services 11
Seegene, Inc. Number of Pipeline Products by Development Stage 12
Seegene, Inc. Pipeline Products Summary by Development Stage 13
Allplex 26-target Respiratory Full Panel - Product Status 14
Allplex 26-target Respiratory Full Panel - Product Description 14
Allplex 27-target Sexually Transmitted Infection Full Panel - Product Status 15
Allplex 27-target Sexually Transmitted Infection Full Panel - Product Description 15
Allplex Gastrointestinal Full Panel Assay - Product Status 16
Allplex Gastrointestinal Full Panel Assay - Product Description 16
Anyplex II HPV HR - Product Status 17
Anyplex II HPV HR - Product Description 17
Anyplex II HSV-1/2 Assay - Product Status 18
Anyplex II HSV-1/2 Assay - Product Description 18
DPO-Based BD Max Assay - Product Status 19
DPO-Based BD Max Assay - Product Description 19
MDx - Cholangiocarcinoma - Product Status 20
MDx - Cholangiocarcinoma - Product Description 20
MDx - Colon Cancer - Product Status 21
MDx - Colon Cancer - Product Description 21
MDx - Non Small Cell Lung Cancer - Product Status 22
MDx - Non Small Cell Lung Cancer - Product Description 22
MDx - Pancreatic Cancer - Product Status 23
MDx - Pancreatic Cancer - Product Description 23
MuDT-Based BD Max Assay - Product Status 24
MuDT-Based BD Max Assay - Product Description 24
Seeplex Sepsis ID Set - Product Status 25
Seeplex Sepsis ID Set - Product Description 25
TOCE-Based BD Max Assay - Product Status 26
TOCE-Based BD Max Assay - Product Description 26
Seegene, Inc., Key Employees 28
Table 1: Seegene, Inc., Other Locations 29
Seegene, Inc., Subsidiaries 29

List of Figures
Seegene, Inc. Pipeline Products by Equipment Type 8
Seegene, Inc. Pipeline Products by Development Stage 12

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • September 2016
  • by Global Markets Direct

Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila Delta Homolog 4 or DLL4) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Delta Like Protein 4 (Delta Like Ligand 4 or Drosophila ...

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘GTPase KRas (KRas 2 or Ki Ras or c K Ras or KRAS or EC 3.6.5.2) - Pipeline ...

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Proto Oncogene Tyrosine Protein Kinase ROS (Proto Oncogene c Ros 1 or Receptor Tyrosine Kinase c Ros Oncogene 1 or c Ros Receptor Tyrosine Kinase or ROS1 or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary ...


ref:plp2016

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.